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Hector Boix  6, Antonio Pavon7, Mercedes Chaffanel8, Isabel Benavente-Fernández9,  
Inés Tofe10, Begoña Loureiro11, José R. Fernández-Lorenzo12, Belén Fernández-Colomer13, 
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Therapeutic hypothermia (TH) initiated within 6 h from birth is the most effective therapeutic approach 
for moderate to severe hypoxic-ischemic encephalopathy (HIE). However, underlying mechanisms 
and effects on the human metabolism are not yet fully understood. This work aims at studying the 
evolution of several energy related key metabolites in newborns with HIE undergoing TH employing 
gas chromatography – mass spectrometry. The method was validated following stringent FDA 
requirements and applied to 194 samples from a subgroup of newborns with HIE (N = 61) enrolled in 
a multicenter clinical trial (HYPOTOP) for the determination of lactate, pyruvate, ketone bodies and 
several Krebs cycle metabolites at different sampling time points. The analysis of plasma samples from 
newborns with HIE revealed a decrease of lactate, pyruvate and β-hydroxybutyrate concentrations, 
whereas rising malate concentrations were observed. In healthy control newborns (N = 19) significantly 
lower levels of pyruvate and lactate were found in comparison to age-matched newborns with HIE 
undergoing TH, whereas acetoacetate and β-hydroxybutyrate levels were clearly increased. Access to 
a validated analytical method and a controlled cohort of newborns with HIE undergoing hypothermia 
treatment for the first time allowed the in-depth study of the evolution of key metabolites of metabolic 
junctions in this special population.
Hypoxic-ischemic encephalopathy (HIE) secondary to perinatal asphyxia is a major cause of mortality and 
long-term neurologic co-morbidities especially occurring in the term neonate. Every year worldwide one million 
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infants die and one million survive with neurological impairment. However, the overall incidence varies notably. 
Hence, while in developed countries the incidence of HIE ranges between 1 and 2 per 1000 live births, in low 
income areas it may account for 26 per 1000 live births1.
Therapeutic hypothermia (TH) initiated within 6 hours from birth2 was introduced to resuscitation guide-
lines in 20103 and involves a core temperature reduction to 33.5 ± 0.5°C for 72 h. Since then hypothermia 
treatment is standard of care for infants with HIE. To date this is the only treatment that has shown to reduce 
death and long-term disability for infants especially with moderate encephalopathy. However, in severe cases 
the combined outcome of death and/or severe disability has not been as successful and still affects around 45% 
of babies4. Therefore, in order to improve outcome of severely affected neonates, new synergistic therapies are 
being explored5,6. To this end, the HYPOTOP trial (EudraCT #2011-005696-17), a randomized, multicenter, 
double blinded placebo-control trial, aiming at the evaluation of the neuroprotective effect of topiramate (TPM) 
in addition to moderate total body hypothermia in patients with HIE, has been carried out. The HYPOTOP trial 
aimed at reducing the hyperexcitability component of HIE which leads to increased neuronal apoptosis. TPM 
has rendered good results in this regard in previously launched pilot studies7. New anticonvulsant drugs such 
as TPM or levetiracetam have shown not to foster apoptosis and even inhibit cascades of damage activated after 
hypoxic-ischemic insults at paediatric doses, indicating that they potentially act as neuroprotectors in addition 
to their antiseizure effects8.
Both, early assessment of the severity of cerebral injury and the prediction of neurological outcomes are cru-
cial for parental counselling, selection of the most appropriate early neuroprotective strategies and/or establish-
ment of multidisciplinary interventions to lessen the severity of chronic morbidities. The diagnosis of an asphyxia 
process that evolves to HIE is based on prenatal clinical information (sentinel events), Apgar scores with special 
emphasis on neurological assessment of tone, response to stimuli or reflexes and cord blood gas analysis reflecting 
metabolic acidosis and increased lactate concentration. Amplitude-integrated electroencephalography (aEEG) in 
the first hours after birth and magnetic resonance imaging (MRI) of the brain and multichannel EEG (mchEEG) 
later on may further confirm the diagnosis5.
Little is known about the evolution of most biochemical markers in newborns with HIE during TH. The sec-
ondary phase of injury is characterized by a failure of oxidative metabolism, which is associated with exhaustion 
of ATP reserves leading to cytotoxic edema, hyperexcitability, cerebral reperfusion and ultimately, cell death by 
necrosis and/or apoptosis. Clinical neurodevelopmental outcomes at 1 and 4 years of age are closely correlated 
with the severity of the secondary failure of oxidative metabolism at 15 h after birth9. Hence, the classical bio-
chemical evaluation of the severity of asphyxia in the first hours of life is based on serial determinations of arterial 
pH, base deficit (BD) and blood lactate10. In practice, they showed reasonable precision for correctly identifying 
absent versus severe HIE. However, due to its remarkable ability to adapt to profound and prolonged hypoxia, 
the healthy foetus frequently is capable of tolerating such insults even without evidence of injury. Hence, BD and 
lactate provide rather imprecise relationship with neonatal encephalopathy for the intermediate group9.
This study reports the evolution of eight metabolites including lactate, pyruvate, metabolites from the Krebs 
cycle and ketone bodies in plasma from newborns with HIE undergoing hypothermia treatment in comparison 
to a control group of samples collected from healthy term newborns. A gas chromatography – mass spectrometry 
(GC-MS) analytical method was developed and successfully validated, allowing the simultaneous quantification 
of the studied metabolites employing a sample volume of only 50 µL, thus enabling serial determinations from 
small volume blood samples. The availability of sound data from a controlled cohort of infants clears the way for 
studying the role of each metabolite in the clinical context of TH in newborns with HIE.
Results
Characteristics of the study population. Characteristics of the studied sub-population of the HYPOTOP 
trial as well as the control group are shown in Table 1. Between both groups, no significant differences were found 
for the gestational age, gender and birth weight. In the control group, the percentage of C-section was significantly 
lower. For all parameters used for the diagnosis of HIE in the delivery room (i.e. Apgar scores, cord pH, BE and 
lactate), highly significant differences were found as expected. Likewise, for treatments related to the resuscitation 
procedure (i.e. positive pressure ventilation, cardiac massage and use of O2 and adrenalin) significant differences 
between both studied populations were obtained.
Quantification of metabolites in plasma samples. Full scan spectra of individual standard solutions 
were recorded during method optimization. Based on the results (data not shown), selected ion monitoring (SIM) 
parameters listed in Table 2 were carefully chosen. Two m/z were recorded for each metabolite for quantification 
and confirmation.
After completing method optimization, analytical figures of merit were assessed during method validation 
including precision, selectivity, lower limit of detection (LLOD), lower limit of quantification (LLOQ), sample 
dilution, carry-over as well as sample and standard stabilities. Method validation was carried out following the 
recommendations of the US Food and Drug Administration (FDA) guidelines for bioanalytical method valida-
tion11. However, since the FDA guideline aims at the quantitative analysis of drugs and their metabolites it cannot 
be directly applied for the measurement of endogenous metabolites due to the lack of blank matrices. This draw-
back has been circumvented applying recovery tests of spiked plasma samples.
Table 2 summarizes the characteristics of the obtained calibration lines for each studied metabolite. 
When possible, linear regression was employed for calibration lines. However, for acetoacetate, succinate and 
α-ketoglutarate the use of a second order polynomial fit was necessary in order to cover a sufficiently wide con-
centration range. With the exception of lactate, signal normalization employing an IS was necessary. All calibra-
tion curves had a coefficient of determination (R2) of ≥0.990.
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Figure 1 shows SIM chromatograms obtained during the analysis of a representative sample before and after 
spiking. It can be observed that in this plasma sample, all studied metabolites were detected with the excep-
tion of fumarate. Chromatographic resolution >1 from other unknown matrix compounds was achieved for all 
metabolites with the exception of malate. High retention time stability (see Table 2), combined with the use of 
two characteristic m/z was used to assure the specificity of the signal. In addition, the Retention Index reported 
in Table 2 was determined for each metabolite and results fitted well with values reported in literature12. LLOQs 
listed in Table 2 were established as the concentration of analyte that can be measured with an imprecision of less 
than 20% and a deviation from target of less than 20% and taking into account the preconcentration factor of 2.4 
achieved during sample processing. The LLOQ was defined as three times the LLOD.
Table 3 shows intra- and inter-day accuracy and precision levels given as % recoveries ± standard deviations 
(s) obtained for standard solutions as well as spiked samples at low, medium and high concentration levels. 
For standard solutions, imprecision determined at each concentration level did not exceed 15%, except for the 
LLOQ, where it did not exceed 20%, while at the same time a deviation from the target concentration of less than 
15% (20% at the LLOQ) was achieved. Results from the recovery study carried out with spiked plasma samples 
revealed the magnitude of matrix effect for each studied metabolite. No significant matrix effect was observed for 
pyruvate, succinate, malate and α-ketoglutarate. In case of the remaining metabolites, recoveries were ranging in 
a ±30% interval for precision as well as accuracy.
The stability of the studied metabolites in standards and samples was assayed under different conditions and 
compared to freshly prepared standards and samples. After three cycles of freeze-thawing, concentrations found 
in standards and samples remained unchanged with recoveries ranging between 81 and 120 and 80 and 114%, 
respectively. After 24 h at 4 °C, which are typical autosampler conditions, metabolites were stable in standards and 
plasma samples with recoveries of 86 to 112 and 93 to 115%, respectively, indicating that injection sequences of up 
to 24 h will not alter the obtained results. No alteration of the measured concentrations was observed (recoveries 
between 86 and 113%) from the analysis of individual aqueous standard solutions stored during 30 days at −20 
°C. Analysis of samples collected and stored at −80 °C for at least two months did not show significant changes 
in determined concentrations (N = 5, p > 0.05), indicating that sample storage under the assayed conditions was 
appropriate, facilitating the application of the method in clinical trials as well as research studies.
Survey of clinical samples. The validated GC-MS method was applied for the analysis of 194 plasma sam-
ples drawn after birth at different points in time from newborns enrolled in the HYPOTOP trial. Figure 2 repre-
sents metabolite concentrations at different sampling time points. Whereas some metabolites (i.e. acetoacetate, 
succinate, fumarate and α-ketoglutarate) remained constant throughout the first three days of life, others showed 
significant changes (two-tailed Wilcoxon rank sum test for equal medians, α = 0.05, p-value for each metabo-
lite shown in Fig. 2) with time. Accordingly, lactate, pyruvate and β-hydroxybutyrate concentrations decreased, 
whereas rising malate concentrations were observed. When comparing metabolite concentrations of newborns 
treated with TPM or placebo stratified by sampling time points, no significant differences were observed at 24 h, 
48 h or 72 h after the administration of the first dose (data not shown).
Furthermore, plasma samples from healthy, term newborns were collected and analysed for the sake of com-
parison. Main descriptors of the distribution of plasma metabolite concentrations of the control group in compar-
ison to newborns subjected to hypothermia treatment 48 h after the administration of the first dose of TPM are 
summarized in Table 4. Significantly lower levels of pyruvate and lactate were found in healthy control newborns, 
whereas acetoacetate and β-hydroxybutyrate levels were clearly increased (two-tailed Wilcoxon rank sum test for 
equal medians, α = 0.05, p-value for each metabolite shown in Table 4).
Discussion
Evidence linking systemic aerobic metabolism and neurological disease in perinatal asphyxia and subsequent 
HIE has been reported in animal models13,14 and in clinical studies15,16. Undoubtedly, whole body moderate hypo-
thermia has substantially increased sequel free survival of newborn infants with moderate to severe HIE. A key 
Parameter Control (N = 19) HYPOTOP (N = 61) p-value
Gestational Age (weeks, mean ± s) 38 ± 2 39 ± 2 >0.05
Gender (% male/female) 53/47 54/46 >0.05
Birth Weight (g ± s) 3200 ± 500 3300 ± 600 >0.05
Type of delivery (% vaginal/C-section) 79/21 44/56 <0.01
Apgar 1 (median (min–max)) 10 (9–10) 1 (0–5) <0.01
Apgar 5 (median (min–max)) 10 (10–10) 3 (0–8) <0.01
Cord pH (mean ± s) 7.31 ± 0.06 6.8 ± 1.0 <0.01
Cord BE (mEq L−1, mean ± s) −2.00 ± 0.04 −16 ± 7 <0.01
Cord lactate (mmol L−1, mean ± s) 4.5 ± 1.6 14 ± 4 <0.01
Positive pressure ventilation (% Yes/No) 0/100 98/2 <0.01
O2>21% (% Yes/No) 0/100 97/3 <0.01
Cardiac Massage (% Yes/No) 0/100 56/44 <0.01
Adrenalin (% Yes/No) 0/100 49/51 <0.01
Table 1. Patients’ characteristics.
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beneficial physiologic effect of TH after perinatal asphyxia is the associated reduction in cerebral and whole-body 
metabolic rates by 5–8% for every 1 °C reduction of core temperature. Yet, a decrease in corporal temperature 
does not simply provoke a slowdown of the metabolism, but alters diverse functions of many macromolecules 
simultaneously, including enzyme activities and transport efficiency, suggesting that cooling leads to coordinated 
effects on multiple regulatory processes17. It can therefore be considered to be of utmost importance to study the 
evolution of key metabolites of metabolic junctions in newborns with HIE undergoing TH in order to gain a bet-
ter understanding of the physiological response of these babies for optimizing clinical monitoring and treatment. 
This work aimed at shedding light into the evolution of several key metabolites related to energy metabolism, 
including lactate, together with pyruvate, the ketone bodies acetoacetate and β-hydroxybutyrate as well as several 
Krebs cycle intermediates, in newborns with HIE receiving TH during the first 72 hours of life (see Fig. 3).
In recent years, several techniques have emerged that allow covering several of those metabolites in a single 
analysis in biological samples providing appropriate levels of sensitivity, accuracy and precision. In the literature, 
mainly GC-MS based methods have been reported18–21. Alternatively, nuclear magnetic resonance16, liquid chro-
matography with fluorescence22 or MS detection23,24 or capillary electrophoresis-MS25,26 have been employed. 
Here, a GC-MS based approach was developed for the quantification of metabolites in plasma samples from 
newborns. The validation study proved that the achieved levels of accuracy and precision were adequate for the 
simultaneous quantification of the set of metabolites in a sample volume of 50 µL.
Concerns about stability of ketone bodies and lactate in plasma samples have been raised and some authors 
propose the use of stabilizing agents for storage27–29. In this study metabolite stability in standards and samples 
was assessed and no significant alterations of concentrations were detected under the tested conditions. Hence, 
it can be concluded that the addition of stabilizing agents was not necessary and helps simplifying the sample 
collection process.
Analyte IS
m/z 
Quantification
m/z 
Confirmation RT ± s [min] RI
Calibration 
Range [µM]
y = ax2 + bx + c
R2 ± s SER
LLOD in 
Plasma [µM]
LLOQ in 
Plasma [µM]a ± s b ± s c ± s
Pyruvate Pyr-13C 174 158 6.00 ± 0.02 1056 0.8–100 — 1.02 ± 0.04 0.0111 ± 0.0016 0.9987 ± 0.0009 3 0.11 0.3
Pyr-13C — 175 — 6.00 ± 0.02 — — — — — — — — —
Lactate — 191 117 6.20 ± 0.02 1068 3.9–1000 — 12000 ± 2000 90000 ± 20000 0.994 ± 0.007 0.3 0.5 1.6
Acetoacetate DMBA 188 89 7.260 ± 0.003 1141 3.1–100 0.011 ± 0.003 0.018 ± 0.008 −0.0007 ± 0.0005 0.9961 ± 0.0012 0.003 0.4 1.3
β-hydroxybutyrate DMBA 191 117 7.640 ± 0.008 1167 0.4–100 — 0.4 ± 0.3 −0.0001 ± 0.0008 0.9983 ± 0.0009 0.7 0.06 0.2
Succinate DMBA 247 147 9.770 ± 0.002 1319 0.1–25 0.17 ± 0.06 0.308 ± 0.014 0.00090 ± 0.00003 0.9965 ± 0.0017 0.08 0.014 0.04
Fumarate DMBA 245 147 10.200 ± 0.002 1351 0.1–25 — 1.4 ± 0.7 0.0002 ± 0.0002 0.994 ± 0.005 0.00007 0.014 0.04
Malate DMBA 147 233 12.130 ± 0.002 1501 0.1–25 — 1.18 ± 0.02 0 ± 0 0.994 ± 0.006 0.02 0.014 0.04
α-ketoglutarate DMBA 198 204 13.20 ± 0.05 1588 0.1–25 0.1536 ± 0.0003 0.19 ± 0.04 0 ± 0 0.996 ± 0.004 0.015 0.014 0.04
DMBA — 239 — 14.700 ± 0.004 — — — — — — — — —
Table 2. Data acquisition parameters and main figures of merit of the quantification method. Note: RT, Standard 
Error of Residuals (SER) measured on Day 1; LLOQs were established as the concentration of analyte that can be 
measured with an imprecision of less than 20% and a deviation from target of less than 20% and taking into 
account the preconcentration factor of 2.4 achieved during sample processing. The LLOQ is defined as three 
times the LOD. RI stands for Retention Index calculated as = × + × − −+RI n t t t t100 100 ( )/( )c n n n1 , where c 
stands for compound of interest, n stands for alkane with n carbon atoms eluting before compound c and +n 1 
stands for alkane with +n 1 carbon atoms eluting after compound c. tc, tn and +tn 1 represent their respective 
retention times.
Figure 1. Chromatograms acquired during the injection of a plasma sample (blue line) and a spiked plasma 
sample (red line). Note: for lactate the 1:10 diluted sample is depicted.
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Under aerobic conditions glucose is metabolized through the glycolytic pathway and penetrates in the mito-
chondria where pyruvate is converted to acetyl coenzyme A, enters the tricarboxylic acid cycle and couples to the 
respiratory chain yielding energy in the form of adenosine triphosphate through oxidative phosphorylation30. In 
capillary blood drawn on day 4 from healthy full-term newborns, lactate and pyruvate were reported to range 
between 367 and 3245 and 10 and 141 μmol L−1, respectively31. In this study, for healthy term newborns at two 
days of age ranges (percentile 10 to 90) between 300 and 1000 and 6 and 50 μmol L−1 (see Table 4) were obtained 
for lactate and pyruvate, respectively. During hypoxia-ischemia decreased cerebral perfusion reduces the delivery 
of oxygen and glucose to the brain. Oxidative phosphorylation is blocked and pyruvate is converted into L-lactate 
through the anaerobic metabolism5,32. Anaerobic metabolism is by far less energy efficient than aerobic metab-
olism leading to energy exhaustion in brain cells. Initial lactate levels are a useful biochemical marker to assess 
the degree of birth asphyxia9,32,33. It has been demonstrated that lactate levels took longer to normalize in asphyx-
iated newborns with moderate to severe neonatal encephalopathy compared with newborns with mild neonatal 
encephalopathy34. In a retrospective case series Balushi et al.32 suggest that lactate levels during the first 4 days of 
life should be carefully monitored in asphyxiated term newborns treated with hypothermia in order to optimize 
handling of those patients and alleviate brain injury. Furthermore, during hypothermia peripheral perfusion is 
significantly decreased and lactate production may indicate hypoxia at tissue level even in the absence of meta-
bolic acidosis35. This study for the first time reports ranges and evolution of lactate values in newborns with HIE 
during TH. This knowledge is important for the interpretation of lactate values of babies during TH monitored in 
the neonatal intensive care unit. In the cohort studied in this clinical trial an increase in lactate levels was found in 
the acute stage and a decreasing tendency with time was observed as expected, revealing a partial restoring of aer-
obic metabolism upon clinical stabilization as a consequence of the energy saving mechanisms triggered by TH.
Pyruvate showed increased levels during the whole examined time period and concentrations also decreased 
with time although remaining elevated as compared to the control group at 48 h of life (see Fig. 2). In rat brain 
tissue, the activation of the anaerobic flux during hypoxia-ischemia and increased glycolysis has been reported 
with all rate-limiting enzymes activated, being the transport of glucose across the blood-brain barrier the 
major rate-limiting step of this process. Consequently, the authors found increased pyruvate and lactate lev-
els in brain during hypoxia-ischemia36. Here, reported results corroborate the accumulation of pyruvate during 
hypoxia-ischemia and show the evolution of its concentration profile during TH.
Whereas in adults glucose is essentially the sole energy fuel for the brain, in neonates the ketone bodies 
acetoacetate and β-hydroxybutyrate derived from ketogenesis in the liver are likely to be as important17,27,37. 
Furthermore ketones have been found to act as neuroprotectors38. In neonates suffering from severe HIE deple-
tion of ketones has been reported suggesting that systemic metabolic responses such as ketogenesis may play a key 
role in preventing neurological injury during asphyxia16. Here, significantly higher levels of both metabolites were 
found in newborns from the control group presumably due to the high fat content of mother’s milk consumed by 
healthy babies. In newborns with HIE, both metabolites showed a decrease with time (although not statistically 
significant for acetoacetate), which might probably be attributed to their consumption as energy fuels. A recent 
study17 revealed that, hypothermia achieves its neuroprotective effects by mediating the cellular acetylation status 
through a coordinated suppression of acetyl-CoA, a metabolite that resides in metabolic junctions of glycolysis, 
amino-acid catabolism and ketosis. Both pyruvate and ketone bodies are major sources for acetyl-CoA, and were 
found to decrease under hypothermia conditions in rat brain.
Succinate accumulation has been associated with severe HIE, possibly evidencing HIF-1α mediated neuro-
logical injury16. Chouchanie et al. showed that the malate/aspartate shuttle and purine nucleotide cycle path-
ways increase fumarate production, which is then converted to succinate by succinate dehydrogenase reversal. 
The selective accumulation of succinate has been described as a universal metabolic signature of ischemia in a 
range of mouse and rat tissues and is thought to be responsible for mitochondrial ROS production that initiate 
ischemia-reperfusion injury39.
The evolution of intermediates of the Krebs cycle has been studied in the HYPOTOP cohort. Determined 
levels of succinate, fumarate, malate, and α-ketoglutarate did not show statistically significant alterations in 
Analyte
Standard solutions - % Accuracy ± s (conc µmol L−1) Spiked plasma samples - % Accuracy ± s (conc µmol L−1)
Intra-day (N = 3) Inter-day (N = 3) Intra-day (N = 3) Inter-day (N = 3)
Low Medium High Low Medium High Low Medium High Low Medium High
Pyruvate 94 ± 20 (0.8) 109 ± 1 (25) 96.8 ± 0.1 (100) 90 ± 6 (0.8) 105 ± 4 (25) 96 ± 3 (100) 92 ± 10 (20) 92 ± 4 (40) 85.0 ± 1.0 (50) 94 ± 7 (20) 97 ± 5 (40) 89 ± 3 (50)
Lactate 115 ± 18 (3.9) 93 ± 7 (250) 97 ± 11 (1000) 114 ± 3 (3.9) 96 ± 3 (250) 99 ± 4 (1000) 69 ± 10 (250) 96 ± 14 (50)* 95 ± 5 (100)* 83 ± 14 (250) 120 ± 30 (50)* 100 ± 30 (100)*
Acetoac 
etate 108 ± 7 (3.1) 96 ± 4 (25) 100.9 ± 1.8 (100) 107.3 ± 0.5 (3.1) 102 ± 8 (25) 100.2 ± 1.6 (100) 70 ± 50 (10) 72 ± 18 (20) 69 ± 7 (50) 90 ± 20 (10) 68 ± 18 (20) 71 ± 14 (50)
β-hydroxy 
butyrate 112.6 ± 1.8 (0.4) 103 ± 6 (25) 97.3 ± 3.8 (100) 103 ± 9 (0.4) 104 ± 3 (25) 97.8 ± 0.4 (100) 65 ± 17 (10) 69 ± 3 (20) 63 ± 3 (50) 77 ± 12 (10) 80 ± 30 (20) 74 ± 13 (50)
Succinate 119 ± 12 (0.1) 100 ± 2 (6.3) 97.9 ± 0.8 (25) 118 ± 9 (0.1) 102 ± 4 (6.3) 97.2 ± 0.6 (25) 85 ± 10 (2) 93 ± 7 (4) 87.0 ± 0.8 (10) 99 ± 16 (2) 110 ± 20 (4) 95 ± 11 (10)
Fumarate 96 ± 2 (0.1) 87 ± 2 (6.3) 105.9 ± 0.9 (25) 103 ± 6 (0.1) 95 ± 7 (6.3) 102 ± 3 (25) 74 ± 8 (2) 80 ± 6 (4) 62.00 ± 0.17 (10) 80 ± 30 (2) 100 ± 30 (4) 80 ± 30 (10)
Malate 94 ± 3 (0.1) 87 ± 2 (6.3) 104.5 ± 0.7 (25) 109 ± 13 (0.1) 94 ± 7 (6.3) 103 ± 3 (25) 82 ± 11 (2) 87 ± 7 (4) 97.0 ± 0.5 (10) 94 ± 17 (2) 100 ± 30 (4) 103 ± 17 (10)
α-ketogl 
utarate 93 ± 16 (0.1) 105 ± 3 (6.3) 96.5 ± 1.1 (25) 100 ± 7 (0.1)
107.6 ± 1.7 
(6.3) 99 ± 2 (25) 97 ± 11 (2) 103 ± 9 (4) 98.0 ± 0.9 (10) 111 ± 12 (2) 111 ± 10 (4) 114 ± 17 (10)
Table 3. Back-calculated accuracy and precision of standard solutions and plasma sample at three spiking 
levels. Note: Values within brackets indicate the concentration of each metabolite in the standard solution/
spiking concentration. *Measured in 1:10 diluted sample.
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comparison to normal control babies. Malate showed an increasing tendency with time, although levels found at 
48 h were not different from those found in the control group.
The HYPOTOP trial aimed at the assessment of the neuroprotective effects of the administration of TPM 
as compared to a placebo. Results presented in this study regarding metabolites involved in central metabolic 
pathways did not reveal any effect of the administration of TPM on metabolite levels. Ongoing studies will focus 
Figure 2. Boxplots of metabolite concentrations in plasma samples from newborns included in the HYPOTOP 
trial. Note: acetoacetate, succinate, malate and α-ketoglutarate detected in 77, 95, 92 and 60% and other analytes 
in 100% of samples, concentrations < LLOQ were set to 1/2xLLOQ; p-values calculated employing the two-
tailed Wilcoxon rank sum test for equal medians.
www.nature.com/scientificreports/
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on the evaluation of the effect of TPM on other metabolic pathways as well as imaging (MRI) and short-and 
long-term clinical outcomes of the babies enrolled in the HYPOTOP trial.
This study has some limitations. Hypothermia for HIE has become a universally accepted standard of care. 
Therefore, energy metabolism derived metabolites in asphyxiated patients without cooling could not be studied 
and compared to patients undergoing hypothermia treatment. Moreover, patients are recruited shortly after birth 
in a severe clinical condition and submitted to acute resuscitation manoeuvres, and cooled within 6 h after birth. 
Intriguingly, we did not find changes in energy-linked metabolites of the tricarboxylic cycle. Remarkably, most 
experimental models lack an active intervention to overcome asphyxia-derived damage. However, in our study 
human newborns were treated with hypothermia, sedation, analgesia and energy supplies in the form of paren-
teral nutrition to overcome the negative consequences of HIE. Altogether these interventions attenuated the rate 
of ATP consumption and enhanced its synthesis during the secondary energy failure phase (5, 6, 7). This allowed 
a satisfactory recovery of most organs of the body such as heart, kidney, intestine, muscle, and liver, while brain 
recovery depended on the initial degree of brain damage during primary energy failure. Determinations were 
carried out in plasma samples reflecting whole body dynamics and not specifically the brain. However, the value 
Metabolite
Control Group HYPOTOP (48 h)
p-valueRange P10-P90 Median Mean ± s >LLOQ (%) Range P10-P90 Median Mean ± s >LLOQ (%)
Pyruvate 6–50 11 100 ± 200 100 12–200 40 100 ± 200 100 1.6 × 10−5
Lactate 300–1000 700 700 ± 400 100 500–3000 1000 1600 ± 2000 100 0.002
Acetoacetate 20–700 100 300 ± 300 100 0.7–30 7 35 ± 130 82 1.7 × 10−8
β-Hydroxybutyrate 13–700 150 300 ± 300 100 4–15 8 9 ± 5 100 4.9 × 10−8
Succinate 0.13–0.7 0.3 0.4 ± 0.3 95 0.11–0.8 0.5 0.4 ± 0.2 100 0.235
Fumarate 0.5–1.1 0.7 0.7 ± 0.2 79 0.3–1.3 0.6 0.8 ± 0.8 100 0.234
Malate 1.0–8 1.2 3 ± 4 100 0.7–5 2 3 ± 4 92 0.535
α-Ketoglutarate 0.5–2 1.2 1.3 ± 0.6 74 0.02–7 1.2 2 ± 4 81 0.672
Table 4. Main descriptors of the distribution of concentrations (µmol L−1) in plasma samples collected from 
the control group (N = 19) and newborns enrolled in the HYPOTOP trial 48 h after the administration of the 
first dose of TPM. Note: p-value calculated employing the two-tailed Wilcoxon rank sum test for equal medians 
(α = 0.05).
Figure 3. Relative changes of metabolites as a function of age of newborns with HIE enrolled in the HYPOTOP 
trial. Note: median values as a relative measure to median values at t0; letter size proportional to concentration 
levels; arrows indicate tendencies.
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of the present study relates to the possibility of studying a big number of patients exquisitely controlled in a rand-
omized controlled trial and opens a very valuable window for future studies.
In conclusion, this work presents data from a validated analytical approach for the determination of eight 
metabolites in small volume plasma samples. Furthermore, it reports for the first time the evolution of metab-
olite levels of newborns suffering from HIE with time during TH. The findings were discussed in the context of 
previously reported studies in animals and humans shedding light into the effect of TH on metabolite levels in 
newborns with HIE.
Materials and Methods
Standards and reagents. Sodium pyruvate, sodium lactate, lithium acetoacetate, sodium β-hydroxybu-
tyrate, disodium succinate, sodium fumarate dibasic, malic acid and α-ketoglutaric acid potassium salt with 
purities >98%, as well as heparin sodium salt, methoxyamine hydrochloride (98%), pyrimidine (≥98%) and 
N-methyl-N-(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (MSTFA + 1% TMCS), pyru-
vate-13C (Pyr13C) (99%) and 3,4-dimetoxibenzoic acid (DMBA) (99%) were purchased from Sigma-Aldrich 
Química SL (Madrid, Spain). Pyr13C and DMBA were used as internal standards (IS). Mixture of C7–C40 n-al-
kanes, each at 1000 g L−1 were acquired from Sigma-Aldrich Química SL (Madrid, Spain). Acetonitrile (ana-
lytical grade) and hexane (analytical grade) were obtained from J.T. Baker (Center Valley, USA) and Scharlau 
(Barcelona, Spain), respectively. Ultrapure H2O was generated with a Milli-Q purification system from Merck 
Millipore (Darmstadt, Germany).
Population. A subgroup of newborns (N = 61) enrolled in the HYPOTOP trial (EU Clinical Trials Register: 
EudraCT 2011-005696-17, start date: 2013-06-18) was included in this study. The flow diagram presented in 
Fig. 4 summarizes the study protocol. Eligible patients were infants >36 weeks’ gestational age that fulfilled the 
following criteria: (1) prenatal signs compatible with hypoxia-ischemia such as alterations of foetal cardiac moni-
toring, abnormal foetal scalp pH (<7.2) or sentinel events such as abruptio placenta, meconium stained amniotic 
fluid or cord prolapse; (2) objective assessment of postnatal depression which included: Apgar ≤5 at 5 min, need 
for resuscitation with positive pressure ventilation for >10 min after birth, cord pH ≤ 7.0 and BE ≥−16 mEq 
L−1 in the worst blood gases obtained in the first 60 min after birth; (3) moderate to severe neurological status 
according to a modified Sarnat & Sarnat scale40. Exclusion criteria included gestational age < 36 weeks, birth 
weight < 2500 g, severe congenital malformations, chromosomopathies, or moribund status.
A total of 194 plasma samples were withdrawn at birth (0 h, corresponding to umbilical cord blood or, if not 
available, the first extracted blood sample, N = 41) and 24 h (N = 51), 48 h (N = 51) and 72 h (N = 51) after the 
administration of the first dose of TPM or placebo. For plasma collection, 0.5 mL of blood was drawn by veni-
puncture employing a heparinized syringe (1% sodium heparin). Plasma was obtained immediately thereafter to 
avoid sample degradation, centrifuging the samples at 1800 g during 10 min at 20°C. Supernatants were imme-
diately collected and stored at −80 °C until analysis. As a control group (N = 19), excess volumes from blood 
samples extracted 53 ± 13 h after birth for routine neonatal screening from healthy term newborns before hospi-
tal discharge were employed and plasma was extracted following the same protocol as described above. Patient 
characteristics are summarized in Table 1. The Ethics Committee for Biomedical Research of the Health Research 
Institute La Fe (Valencia, Spain) approved the study protocol. Informed consent was obtained from parents of all 
participants. All methods were performed in accordance with the relevant guidelines and regulations.
Preparation of stock, working and standard solutions. 5 mL of individual stock solutions of pyru-
vate, lactate, acetoacetate, β-hydroxybutyrate, succinate, fumarate, malate and α-ketoglutarate at a concentration 
of 1 mmol L−1 were prepared in H2O by weighing of pure solid analytical standards in volumetric flasks. 1 mL 
aliquots of each standard solution were stored at −20 °C in order to avoid freeze-thawing of standard solu-
tions. 500 µL of a working solution containing 1000 µmol L−1 of lactate, 100 µmol L−1 of pyruvate, acetoacetate 
Figure 4. Flow diagram of the HYPOTOP trial.
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and β-hydroxybutyrate and 25 µmol L−1 of succinate, fumarate, malate and α-ketoglutarate was prepared in 
H2O:CH3CN (1:4 v/v). 10 standard solutions were obtained by serial dilution from the working solution 
with H2O: CH3CN (1:4 v/v). Concentrations were ranging between 3.9 and 1000 µmol L−1 for lactate, 0.4 and 
100 µmol L−1 for pyruvate, acetoacetate and β-hydroxybutyrate and 0.1 and 25 µmol L−1 for succinate, fumarate, 
malate and α-ketoglutarate. On each of the three validation days, 500 µL of spiking solution was prepared in 
H2O:CH3CN (1:4, v/v) containing 10 mmol L−1 of lactate, 800 µmol L−1 of pyruvate, 400 µmol L−1 of acetoacetate 
and β-hydroxybutyrate and 80 µmol L−1 of succinate, fumarate, malate and α-ketoglutarate.
Biomarker analysis of plasma samples. Prior to analysis, standards and samples were derivatised in a 
two-step oximation-silylation procedure. Blanks were prepared in the same way as plasma samples, replacing the 
plasma volume with H2O.
Plasma samples were thawed on ice and homogenized on a vortex mixer during 30 s. 250 µL of cold (4 °C) 
CH3CN were added to 50 µL of plasma. Samples were maintained on ice during 5 min followed by centrifugation 
at 11000 g during 10 min at 4 °C. 200 µL of supernatant or standard solution were transferred to an Eppendorf® 
tube and 8 and 4 µL of Pyr13C and DMBA, both at a concentration of 1 mM were added, respectively. For the 
recovery test, spiked samples at three concentration levels (i.e. low, medium and high) were prepared by adding 
2.5, 5 or 10 µL of spiking solution in addition to the IS. Samples and standards were evaporated on a SpeedVac 
concentrator from Genevac Ltd (Ipswich, UK) at 40 °C. Dry residues were suspended in 20 µL of a freshly pre-
pared 4% (w/w) methoxyamine solution in pyridine. Samples and standards were incubated during 90 min at 
30 °C on a thermomixer (MKR 13, Ditabis) under agitation. Then, 20 µL MSTFA + 1% TMCS were added. After 
30 min of reaction time at 37 °C under agitation, samples and standards were diluted with 40 µL of hexane and 
placed in capped glass vials for GC-MS analysis. Samples were re-analysed after 1:10 dilution with hexane in case 
analyte concentrations exceed the established quantification range.
A 6890GC-5973N gas chromatography electron impact quadrupole mass spectrometric (GC-(EI)-Q-MS) 
system equipped with an autosampler and a HP-5MS column (0.25 mm × 30 m, film thickness 0.25 µm (5% 
Phenyl)-methylpolysiloxane) from Agilent Technologies (Santa Clara, CA, USA) were employed for sample anal-
ysis. The GC was operated at a constant He carrier gas flow at a flow rate of 1.2 mL min−1. The injector tempera-
ture was set to 260 °C and 1 µL of sample was injected at a split ratio of 5:1. The oven temperature was maintained 
at 60 °C during 1 min followed by a linear gradient of 10 °C min−1 until reaching 310 °C which were held during 
10 min. The total runtime was 36 min.
Data Availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request.
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